Replies to post #8091 on GTC Biotherapeutics (fka GTCB)

[makarios]

I must admit I do not know much about their execution on the financial front enough to offer another perspective on it...I look at it this way, I"m a long term believer in this company and looking back, in 5, 10, 15 years, sure I'll be disappointed that my investment was diluted, but not enough for it to affect my decision to move forward. OF course, given future failures/disappointments on the financial front I will consider selling part, but it's not a worry of mine considering my cost basis is <1...i'm fortunate, i know.

What are the consequences, other than dilution, that you REALISTICALLY perceive or anticipate? If it's dilution, i'm not worried too much, but if they are in danger of a hostile takeover, or getting scattered into the winds, then i'm worried.

But again, i do not know much about their past financial execution failures/disappointments beyond past year 1/2, so if you see consequences beyond dilution as a threat than I would love to be informed, as I am not.

P.s. this is my last allowable post for the day

[scissors]

I suspect GTCB management got caught with their pants down. They announced an imminent partnership agreement and even considered income from the deal in 2007. The deal must have fallen through and then, woops, GTCB needs to desparately come up with working capital in a bad borrowing environment. So they dilute to get the up-front cash they had counted on from inking a partnership deal. Shame on them for trusting their prospective partner(s) to make good. Perhaps they learned some hard lessons dancing with the elephants because now the vultures may be circling. Their best hope is to find prospective partners who are willing to compete for the business with bids that include up front cash or easy milestones. Without that they are in trouble, particularly if the FDA drags its feet. I'm tired of averaging down. I will sit on the sidelines for now and keep my fingers crossed.